Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8206551 | 0.85 | CA2 (0.37) | CA2CA12CA14DGAT1HDAC6 | |
| SCHEMBL410255 | 0.82 | CA2 (0.40) | CA2CA12CA14DGAT1HDAC6 | |
| Hydrochloric Acid SCHEMBL219630 | 0.80 | CA2 (0.39) | CA2CA12CA14DGAT1HDAC6 | |
| Hydrochloric Acid SCHEMBL31480795 | 0.80 | CA2 (0.39) | CA2CA12CA14DGAT1HDAC6 | |
| SCHEMBL9787667 | 0.80 | HDAC6 (0.34) | CA2CA12CA14DGAT1HDAC6 | |
| SCHEMBL5329667 | 0.80 | CA12 (0.34) | CA2CA12CA14DGAT1HDAC6 | |
| SCHEMBL8206554 | 0.79 | CA2 (0.33) | CA2CA12CA14DGAT1HDAC6 | |
| SCHEMBL28061441 | 0.78 | HDAC6 (0.36) | CA2CA12CA14DGAT1HDAC6 | |
| SCHEMBL29004075 | 0.77 | RECQL (0.36) | CA2CA12CA14DGAT1TDP1 | |
| SCHEMBL124341 | 0.77 | ALDH1A1 (0.41) | TDP1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12415789-B2 | Macrocycles comprising a 4-amido-2,4-pentadienoate moiety for the treatment of hypoxic cancers | AARHUS UNIVERSITET (DK) | 2025-09-16 | — | — | US | disclosed |
| CN-119462517-A | NLRP3 inflammation corpuscle inhibitor and application thereof | 药捷安康(南京)科技股份有限公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-118420607-A | Heteroaromatic compounds and uses thereof | 希格生科（深圳）有限公司 | 2024-08-02 | — | — | CN | disclosed |
| CN-118164865-A | Preparation method of sarcosine hydrochloride | 四川什邡市三高生化实业有限公司 | 2024-06-11 | — | — | CN | disclosed |
| CN-114751927-B | Boric acid compound, preparation method and application | 中山大学 | 2023-10-31 | — | — | CN | disclosed |
| CN-116670120-A | Process for preparing carboxylic cyclic anhydride | 北京大学 | 2023-08-29 | — | — | CN | disclosed |
| CN-115317493-B | Application of boric acid micromolecule compound in preparation of drugs for enhancing curative effect of immune checkpoint inhibitor and treating leukemia | 中山大学 | 2023-04-28 | — | — | CN | disclosed |
| US-20230020952-A1 | MACROCYCLES COMPRISING A 4-AMIDO-2,4-PENTADIENOATE MOIETY FOR THE TREATMENT OF HYPOXIC CANCERS | AARHUS UNIVERSITET (DK) | 2023-01-19 | — | — | US | disclosed |
| WO-2021110968-A1 | MACROCYLCES COMPRISING A 4-AMIDO-2,4-PENTADIENOATE MOIETY FOR THE TREATMENT OF HYPOXIC CANCERS | AARHUS UNIVERSITET (DK) | 2021-06-10 | — | — | WO | disclosed |
| WO-2000001714-A1 | EFFLUX PUMP INHIBITORS | MICROCIDE PHARMACEUTICALS, INC. (US) | 2000-01-13 | — | — | WO | disclosed |
| EP-0205362-B1 | QUINOLYL GLYCINAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR PHARMACEUTICAL USE AS PSYCHOTROPES | SANOFI (FR) | 1989-12-20 | — | — | EP | disclosed |
| EP-0205362-A1 | Quinolyl glycinamide derivatives, process for their preparation and their pharmaceutical use as psychotropes | SANOFI (FR) | 1986-12-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230020952-A1 | MACROCYCLES COMPRISING A 4-AMIDO-2,4-PENTADIENOATE MOIETY FOR THE TREATMENT OF HYPOXIC CANCERS | DLD, HIF1A, DPYD | CA2 1246/4885CA12 1780/4885CA14 1197/4885 |
| US-12415789-B2 | Macrocycles comprising a 4-amido-2,4-pentadienoate moiety for the treatment of hypoxic cancers | DLD, HIF1A, DPYD | CA2 1246/4885CA12 1780/4885CA14 1197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.